# Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer

> **NCT03333824** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 33 (actual)

## Conditions studied

- Solid Tumours

## Interventions

- **DRUG:** CYP1A2 (caffeine)
- **DRUG:** CYP2C19 (omeprazole)
- **DRUG:** CYP3A (midazolam)
- **DRUG:** Kytril (granisetron)
- **DRUG:** Wee-1 kinase inhibitor AZD1775

## Key facts

- **NCT ID:** NCT03333824
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-01
- **Primary completion:** 2019-01-22
- **Final completion:** 2019-01-22
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2019-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03333824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03333824, "Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03333824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*